Purple Biotech Ltd Total Liabilities
Purple Biotech Ltd total liabilities. Based on the latest financial reports, Purple Biotech Ltd (KTOV) has total liabilities worth ILA29.64 Million ILA (≈ $79.46K USD) as of June 2020. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Purple Biotech Ltd defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Purple Biotech Ltd (2009–2019)
Total liabilities of Purple Biotech Ltd from 2009 to 2019. This chart illustrates how Purple Biotech Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Purple Biotech Ltd (KTOV) asset resilience to evaluate the company's liquid asset resilience ratio.
Purple Biotech Ltd Competitors by Total Liabilities
The table below lists competitors of Purple Biotech Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Reliance Industries Limited
IL:RIGD
|
UK | $10.92 Trillion |
|
Appili Therapeutics Inc
TO:APLI
|
Canada | CA$16.93 Million |
|
Setubandhan Infrastructure Limited
NSE:SETUINFRA
|
India | Rs2.29 Billion |
|
Naked Wines plc
LSE:WINE
|
UK | GBX107.52 Million |
|
SECITS Holding AB (publ)
ST:SECI
|
Sweden | Skr83.32 Million |
|
Steakholder Foods Ltd
NASDAQ:STKH
|
USA | $877.00K |
|
Upsellon Brands Holdings Ltd
TA:CHR
|
Israel | ILA2.01 Million |
|
China SXT Pharmaceuticals Inc
NASDAQ:SXTC
|
USA | $5.05 Million |
Liability Composition Analysis (2009–2019)
This chart breaks down Purple Biotech Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Purple Biotech Ltd balance sheet assets.
Liquidity & Leverage Metrics
Purple Biotech Ltd Total Liabilities Ratios Explained
Purple Biotech Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Purple Biotech Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Purple Biotech Ltd (2009–2019)
The table below shows the annual total liabilities of Purple Biotech Ltd from 2009 to 2019.
| Year | Total Liabilities | Change |
|---|---|---|
| 2019-12-31 | ILA3.86 Million ≈ $10.35K |
+3.76% |
| 2018-12-31 | ILA3.72 Million ≈ $9.97K |
-33.47% |
| 2017-12-31 | ILA5.59 Million ≈ $14.99K |
+265.60% |
| 2016-12-31 | ILA1.53 Million ≈ $4.10K |
+10.56% |
| 2015-12-31 | ILA1.38 Million ≈ $3.71K |
+52.31% |
| 2014-12-31 | ILA908.00K ≈ $2.43K |
-27.76% |
| 2013-12-31 | ILA1.26 Million ≈ $3.37K |
+5613.64% |
| 2012-12-31 | ILA22.00K ≈ $58.98 |
-99.47% |
| 2011-12-31 | ILA4.15 Million ≈ $11.12K |
+24.49% |
| 2010-12-31 | ILA3.33 Million ≈ $8.93K |
+31.44% |
| 2009-12-31 | ILA2.54 Million ≈ $6.80K |
-- |
About Purple Biotech Ltd
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension i… Read more